NCT06481345View on ClinicalTrials.gov

Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)

Active, not recruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Myeloproliferative Disorders

Trial Locations (1)

29609

Chu Brest, Brest

All Listed Sponsors

lead

University Hospital, Brest

OTHER

NCT06481345 - Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM) | Biotech Hunter | Biotech Hunter